TNFRSF18 and neoplasm: All other analysed receptors, which were lineage markers (CD3, CD14, CD16, CD19, CD20, CD56), Fc-receptors (CD16, CD23, CD32, CD64), further T cell markers (CD1a, CD2, CD3, CD5, CD8, CD25, GITR, CTLA-4), activation markers (CD40, CD69), stem cell markers (CD34, CD117, CD133) and the myeloid marker CD11c, were not significantly affected by tumor cell-lines in the classical PDC population (data not shown).